

Brensocaticib for Non-Cystic Fibrosis Bronchiectasis

Stakeholder List

ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.

The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER's outreach or agreed to participate in this review.

- COPD Foundation DBA The Bronchiectasis and NTM Association
- National Health Council
- NTM Info & Research

We engaged with several additional experts in the preparation of this report. Of them, the following individuals have agreed to be identified as having engaged with ICER:

- **Dr. Alan Barker, MD**, Professor of Medicine, Division of Pulmonary and Critical Care Medicine Oregon Health and Science University
- **Dr. Walter O'Donnell, MD**, Assistant Professor of Medicine, Harvard Medical School, Director, Centre for Humane Innovations in Clinical Care (CHICC), Massachusetts General Hospital

To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.

None of these individuals or organizations is responsible for the final content of ICER's report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).